Odyssey Health, Inc.
ODYY evidence brief
What we can confirm
- BioSniper Score:
- 4.7 / 10
- Market Cap:
- $1.0M
- Lead Asset:
- cardiomap (Preclinical)
What it means
What to watch
Prepared research question
What matters most for ODYY—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ODYY
Odyssey Health, Inc. (ODYY) is a pre-revenue medical technology acquisition and development company with two early-stage product candidates — the CardioMap heart monitoring device and the Save-A-Life choking rescue device — and a preclinical neurosteroid program (ONP-002/ONP-001) that was sold to Oragenics, Inc. in an asset sale.
Key risk: No revenue or approved products
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$1.0M
Cash Runway
—
Lead Asset
cardiomap (Preclinical)
Next Catalyst
—
Financial data as of Apr 30, 2026.
Tracking 5 pipeline candidates for Odyssey Health, Inc..
Odyssey Health, Inc. (ODYY) is a pre-revenue medical technology acquisition and development company with two early-stage product candidates — the CardioMap heart monitoring device and the Save-A-Life choking rescue device — and a preclinical neurosteroid program (ONP-002/ONP-001) that was sold to Oragenics, Inc. in an asset sale.
- Odyssey Health has two technologies in development: the CardioMap heart monitoring and screening device and the Save-A-Life choking rescue device [sec_mda · as of 2026-06-12].
- The company sold its brain-related product segment (ONP-002 and ONP-001) to Oragenics, Inc. for $1,000,000 cash and 8,000,000 shares of convertible Series F Preferred Stock [pipeline].
- As of 2026-04-30, Odyssey reported net income of $0.8M and negative shareholders' equity of -$9.7M [sec].
- The company has no revenue and no product candidates that have received regulatory clearance or approval for commercial sale [sec_mda · as of 2026-06-12].
- A Phase 2a study of OD-0765 (NCT06850727) is recruiting, evaluating safety and efficacy via the 3-component modified Mayo Clinic Score [catalyst · 2025-06-02].
What works
- Odyssey has a diversified pipeline with two device technologies (CardioMap and Save-A-Life) and a preclinical neurosteroid program, spreading development risk [sec_mda · as of 2026-06-12].
- The company has initiated a Phase 2a clinical trial (OD-0765) and is actively recruiting, indicating progress toward clinical validation [catalyst · 2025-06-02].
- The asset sale of ONP-002/ONP-001 to Oragenics provided $1,000,000 cash and equity, generating non-dilutive funding [pipeline].
What to weigh
- Odyssey has no revenue and no product candidates that have received regulatory clearance or approval for commercial sale [sec_mda · as of 2026-06-12].
- The company's shareholders' equity is deeply negative at -$9.7M as of 2026-04-30, indicating a weak capital position [sec].
- The company acknowledges substantial inherent risks in commercializing newly developed products and that commercial feasibility and acceptance are unknown [sec_mda · as of 2025-10-29].
- Odyssey has a limited operating history and no revenue on which to evaluate its ability to achieve business objectives or projected cash needs [sec_mda · as of 2025-10-29].
From the filings
Quoted directly from source documents.
Odyssey has two device technologies in development.
“We have two different technologies in development; the CardioMap heart monitoring and screening device and the Save-A-Life choking rescue device.”
SEC MD&A · June 12, 2026
The company sold its brain-related product segment to Oragenics.
“Asset sale of brain-related product segment including ONP-002 and ONP-001 for $1,000,000 cash and 8,000,000 shares of convertible Series F Preferred Stock.”
Odyssey has no revenue and no regulatory clearance.
“To date, none of our product candidates have received regulatory clearance or approval for commercia”
SEC MD&A · June 12, 2026
Catalyst timeline
- 2025-06-02 · Phase 2a start for OD-0765 — A Phase 2a, open-label and randomized study evaluating safety and efficacy of OD-0765 via the 3-component modified Mayo Clinic Score; currently recruiting.
Risks & what to watch (4)›
Key risks
- No revenue or approved products — Odyssey has no revenue and no product candidates that have received regulatory clearance or approval for commercial sale [sec_mda · as of 2026-06-12].
- Negative shareholders' equity — Shareholders' equity is -$9.7M as of 2026-04-30, indicating a weak capital position [sec].
- Commercialization risk — The company acknowledges substantial inherent risks in commercializing newly developed products and that commercial feasibility is unknown [sec_mda · as of 2025-10-29].
- Limited operating history — Odyssey has a limited operating history and no revenue on which to evaluate its ability to achieve business objectives [sec_mda · as of 2025-10-29].
What to watch
- Progress and results of the Phase 2a study of OD-0765 (NCT06850727), which is currently recruiting [catalyst · 2025-06-02].
- Development milestones for the Save-A-Life choking rescue device, which has a prototype and plans for further advancement [news · published 2025-08-26].
- Any updates on the CardioMap heart monitoring device, which remains in the research and development stage [sec_mda · as of 2026-06-12].
- Financial runway and cash position, given the negative equity and lack of revenue [sec].
Sources: Catalysts · News · Pipeline · SEC MD&A · Generated September 25, 2026 · How we verify sources →
Run Odyssey Health, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Odyssey Health, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
Net income $766K
Lead: Preclinical
5 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Frequently asked questions
What is the AI investment thesis for Odyssey Health, Inc.?
Odyssey Health, Inc. (ODYY) is a pre-revenue medical technology acquisition and development company with two early-stage product candidates — the CardioMap heart monitoring device and the Save-A-Life choking rescue device — and a preclinical neurosteroid program (ONP-002/ONP-001) that was sold to Oragenics, Inc. in an asset sale.
What is Odyssey Health, Inc.'s lead drug candidate?
Odyssey Health, Inc.'s most advanced tracked candidate is cardiomap (Preclinical) for heart monitoring and screening.
Who is the CEO of Odyssey Health, Inc.?
Mr. Joseph Michael Redmond is the chief executive officer of Odyssey Health, Inc. (ODYY).
Where is Odyssey Health, Inc. headquartered?
Odyssey Health, Inc. (ODYY) is headquartered in Las Vegas, NV, United States.
What therapeutic areas does Odyssey Health, Inc. focus on?
Odyssey Health, Inc. develops therapies across Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.